相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD40 Agonist Antibodies in Cancer Immunotherapy
Robert H. Vonderheide
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Christopher S. Garris et al.
CLINICAL CANCER RESEARCH (2020)
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Alexander H. Morrison et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
A conserved dendritic-cell regulatory program limits antitumour immunity
Barbara Maier et al.
NATURE (2020)
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Floris Dammeijer et al.
CANCER CELL (2020)
cDC1 prime and are licensed by CD4+T cells to induce anti-tumour immunity
Stephen T. Ferris et al.
NATURE (2020)
Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling
Anthony C. Antonelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Management of metastatic bladder cancer
Rosa Nadal et al.
CANCER TREATMENT REVIEWS (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
Sandra M. M. Irenaeus et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity
Hayley S. Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review
Manmeet Saluja et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy
Ryoichi Saito et al.
CANCER RESEARCH (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Caroline Pettenati et al.
NATURE REVIEWS UROLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
David A. Knorr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guerin
Jathin Bandari et al.
EUROPEAN UROLOGY FOCUS (2018)
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Gregory L. Beatty et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
BCG-unresponsive non-muscle invasive bladder cancer: recommendations from the IBCG
Ashish M. Kamat et al.
NATURE REVIEWS UROLOGY (2017)
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
Manisha Singh et al.
NATURE COMMUNICATIONS (2017)
The transcription factor Batf3 inhibits the differentiation of regulatory T cells in the periphery
Wonyong Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer
Benjamin A. Kansy et al.
CANCER RESEARCH (2017)
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
Christina S. Baik et al.
CLINICAL CANCER RESEARCH (2017)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Yonit Lavin et al.
CELL (2017)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts et al.
CANCER CELL (2016)
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor
Shin Foong Ngiow et al.
CANCER RESEARCH (2016)
Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species
Martin Guilliams et al.
IMMUNITY (2016)
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
Katelyn T. Byrne et al.
CELL REPORTS (2016)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity (vol 26, pg 638, 2014)
Miranda L. Broz et al.
CANCER CELL (2014)
Type I and type II Fc receptors regulate innate and adaptive immunity
Andrew Pincetic et al.
NATURE IMMUNOLOGY (2014)
Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop
Jonathan P. Jarow et al.
UROLOGY (2014)
Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
F. Chowdhury et al.
CANCER IMMUNOLOGY RESEARCH (2014)
BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model
Cyrill A. Rentsch et al.
PLOS ONE (2013)
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
Fubin Li et al.
CELL CYCLE (2012)
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Patrick Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Claire Biot et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
Richard R. Furman et al.
LEUKEMIA & LYMPHOMA (2010)
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
Kai Hildner et al.
SCIENCE (2008)
CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation
DP Inwald et al.
CIRCULATION RESEARCH (2003)
Bladder permeability barrier: recovery from selective injury of surface epithelial cells
J Lavelle et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2002)
分享论文
